Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Brantley Sieders, Dana M ^b   Jiang, Aixiang ^b,c   Sarma, Krishna ^b   Badu Nkansah, Akosua ^b   Walter, Debra L ^b   Shyr, Yu ^b,c   Chen, Jin ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN; EPHRIN A2; EPHRIN A4; EPHRIN A7; EPHRIN B4; EPHRIN B6; EPHRIN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; EPHRIN A1; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR A7; EPHRIN RECEPTOR B4; EPHRIN RECEPTOR B6;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM;

BREAST NEOPLASMS; EPHRIN-A1; EPHRINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, EPHA2; RECEPTOR, EPHA4; RECEPTOR, EPHA7; RECEPTOR, EPHB4; RECEPTOR, EPHB6; TISSUE ARRAY ANALYSIS;

EID: 80052851917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024426     Document Type: Article

References (46)

1. Michael S, Charikleia S, Konstantinos K, (2011) Lymphedema and breast cancer: a review of the literature. Breast Cancer.
2. Azim HA, de Azambuja E, Colozza M, Bines J, Piccart MJ, (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol.
3. Stewart FA, Hoving S, Russell NS, (2010) Vascular Damage as an Underlying Mechanism of Cardiac and Cerebral Toxicity in Irradiated Cancer Patients. Radiat Res.
4. Tonezzer T, Pereira CM, Filho UP, Marx A, (2010) Hormone therapy/adjuvant chemotherapy induced deleterious effects on the bone mass of breast cancer patients and the intervention of physiotherapy: a literature review. Eur J Gynaecol Oncol 31: 262-267.
5. Pasquale EB, (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
6. Brantley-Sieders DM, Chen J, (2004) Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 7: 17-28.
7. Brantley-Sieders D, Schmidt S, Parker M, Chen J, (2004) Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10: 3431-3442.
8. Vaught D, Brantley-Sieders DM, Chen J, (2008) Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res 10: 217.
9. Lackmann M, Boyd AW, (2008) Eph, a protein family coming of age: more confusion, insight, or complexity? Sci Signal 1: re2.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
11. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
12. Vaught D, Chen J, Brantley-Sieders DM, (2009) Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell 20: 2572-2581.
13. Kouros-Mehr H, Werb Z, (2006) Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 235: 3404-3412.
14. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, et al. (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026.
15. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, et al. (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052.
16. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS, (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306.
17. Pan M, (2005) Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status. J of Clin Oncol [Meeting Abstracts] 23: 9583.
18. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, et al. (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118: 64-78.
19. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J, (2005) A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24: 7859-7868.
20. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, et al. (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70: 299-308.
21. Gokmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, et al. (2010) Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat.
22. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, et al. (2004) Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10: 26-33.
23. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, et al. (2006) Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169: 279-293.
24. Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, et al. (2002) Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 115: 25-37.
25. Berclaz G, Andres AC, Albrecht D, Dreher E, Ziemiecki A, et al. (1996) Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 226: 869-875.
26. Berclaz G, Flutsch B, Altermatt HJ, Rohrbach V, Djonov V, et al. (2002) Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 9: 985-989.
27. Noren NK, Foos G, Hauser CA, Pasquale EB, (2006) The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815-825.
28. Noren NK, Pasquale EB, (2007) Paradoxes of the EphB4 receptor in cancer. Cancer Res 67: 3994-3997.
29. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, et al. (2009) EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 114: 1707-1716.
30. Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, et al. (2010) Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol 41: 48-58.
31. Fox BP, Kandpal RP, (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882-892.
32. Fox BP, Tabone CJ, Kandpal RP, (2006) Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 342: 1263-1272.
33. Fox BP, Kandpal RP, (2009) EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 28: 1706-1713.
34. Fox BP, Kandpal RP, (2010) DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation. Cancer Genomics Proteomics 7: 9-16.
35. Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A, (2010) The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res 70: 1141-1153.
36. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, et al. (2005) A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118.
37. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, et al. (2001) Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3: 527-530.
38. Guo H, Miao H, Gerber L, Singh J, Denning MF, et al. (2006) Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 66: 7050-7058.
39. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, et al. (2005) EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47.
40. Frieden LA, Townsend TA, Vaught DB, Delaughter DM, Hwang Y, et al. (2010) Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev Dyn 239: 3226-3234.
41. Team RDC, (2010) R: A language and environment for statistical computing Vienna, Austria R. Foundation for Statistical Computing.
42. Harrington DP, Fleming TR, (1982) A class of rank test procedures for censored survival data. Biometrika 69: 553-566.
43. Newson R, (2006) Confidence intervals for rank statistics: Somers' D and extensions. The Stata Journal 6: 309-334.
44. Therneau TM, Grambsch PM, (2000) Modeling survival data: extending the Cox model; In: Dietz K, Gail M, Krickeberg K, Samet J, Tsiatis A, editors. New York Springer-Verlag.
45. Ripley BD, (1987) Stochastic Simulation New York John Wiley and Sons.
46. Becker RA, Chambers JM, Wilks AR, (1998) The New S Language: A Programming Environment for Data Analysis and Graphics; In: Brookscole Wa, editors. Boca Raton, FL Chapman and Hall/CRC Press.